214 related articles for article (PubMed ID: 21906275)
21. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy.
Lee JM; Yin KJ; Hsin I; Chen S; Fryer JD; Holtzman DM; Hsu CY; Xu J
Ann Neurol; 2003 Sep; 54(3):379-82. PubMed ID: 12953271
[TBL] [Abstract][Full Text] [Related]
22. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.
Racke MM; Boone LI; Hepburn DL; Parsadainian M; Bryan MT; Ness DK; Piroozi KS; Jordan WH; Brown DD; Hoffman WP; Holtzman DM; Bales KR; Gitter BD; May PC; Paul SM; DeMattos RB
J Neurosci; 2005 Jan; 25(3):629-36. PubMed ID: 15659599
[TBL] [Abstract][Full Text] [Related]
23. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
24. Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ; Liu B; Frost JL; Lemere CA
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
[TBL] [Abstract][Full Text] [Related]
25. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
Zara S; Rapino M; Sozio P; Di Stefano A; Nasuti C; Cataldi A
Brain Res; 2011 Sep; 1412():79-87. PubMed ID: 21820649
[TBL] [Abstract][Full Text] [Related]
26. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA
Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
[TBL] [Abstract][Full Text] [Related]
27. Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein.
Li W; Poteet E; Xie L; Liu R; Wen Y; Yang SH
Brain Res; 2011 Apr; 1387():141-8. PubMed ID: 21376707
[TBL] [Abstract][Full Text] [Related]
28. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.
Frost JL; Liu B; Kleinschmidt M; Schilling S; Demuth HU; Lemere CA
Neurodegener Dis; 2012; 10(1-4):265-70. PubMed ID: 22343072
[TBL] [Abstract][Full Text] [Related]
29. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.
Wilcock DM; Colton CA
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):50-64. PubMed ID: 19275636
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for Alzheimer's disease: will vaccination work?
Dodart JC; Bales KR; Paul SM
Trends Mol Med; 2003 Mar; 9(3):85-7. PubMed ID: 12657428
[TBL] [Abstract][Full Text] [Related]
32. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.
Chauhan NB; Siegel GJ
J Neurosci Res; 2003 Oct; 74(1):142-7. PubMed ID: 13130516
[TBL] [Abstract][Full Text] [Related]
33. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
35. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
Crehan H; Liu B; Kleinschmidt M; Rahfeld JU; Le KX; Caldarone BJ; Frost JL; Hettmann T; Hutter-Paier B; O'Nuallain B; Park MA; DiCarli MF; Lues I; Schilling S; Lemere CA
Alzheimers Res Ther; 2020 Jan; 12(1):12. PubMed ID: 31931873
[TBL] [Abstract][Full Text] [Related]
36. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
[TBL] [Abstract][Full Text] [Related]
38. Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice.
Biscaro B; Lindvall O; Hock C; Ekdahl CT; Nitsch RM
J Neurosci; 2009 Nov; 29(45):14108-19. PubMed ID: 19906959
[TBL] [Abstract][Full Text] [Related]
39. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML
Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740
[TBL] [Abstract][Full Text] [Related]
40. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A
Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
